Ramucirumab as a second-line treatment for hepatocellular carcinoma: reaching out further to patients with elevated alpha-fetoprotein

Affiliations

¹ Gastroenterology Unit, Department of Internal Medicine, Ospedale Policlinico San Martino IRCCS per l'Oncologia, University of Genoa, Genoa, Italy.
² Medical Semeiotics Unit, Sant'Orsola Hospital, Alma Mater Studiorum University of Bologna, Bologna, Italy.

Editorial

Edoardo G Giannini et al. Hepatobiliary Surg Nutr. 2019 Oct.

. 2019 Oct;8(5):515-518.

doi: 10.21037/hbsn.2019.04.19.

¹ Gastroenterology Unit, Department of Internal Medicine, Ospedale Policlinico San Martino IRCCS per l'Oncologia, University of Genoa, Genoa, Italy.
² Medical Semeiotics Unit, Sant'Orsola Hospital, Alma Mater Studiorum University of Bologna, Bologna, Italy.

No abstract available

Conflict of interest statement

Conflicts of Interest: The authors have no conflicts of interest to declare.

Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial.
Zhu AX, Kang YK, Yen CJ, Finn RS, Galle PR, Llovet JM, Assenat E, Brandi G, Pracht M, Lim HY, Rau KM, Motomura K, Ohno I, Merle P, Daniele B, Shin DB, Gerken G, Borg C, Hiriart JB, Okusaka T, Morimoto M, Hsu Y, Abada PB, Kudo M; REACH-2 study investigators. Zhu AX, et al. Lancet Oncol. 2019 Feb;20(2):282-296. doi: 10.1016/S1470-2045(18)30937-9. Epub 2019 Jan 18. Lancet Oncol. 2019. PMID: 30665869 Clinical Trial.

1. Sangiovanni A, Prati GM, Fasani P, et al. The natural history of compensated cirrhosis due to hepatitis C virus: A 17-year cohort study of 214 patients. Hepatology 2006;43:1303-10. 10.1002/hep.21176 - DOI - PubMed
1. Italian Association for the Study of the Liver (AISF) AISF Expert Panel ; AISF Coordinating Committee, et al. Position paper of the Italian Association for the Study of the Liver (AISF): the multidisciplinary clinical approach to hepatocellular carcinoma. Dig Liver Dis 2013;45:712-23. 10.1016/j.dld.2013.01.012 - DOI - PubMed
1. Giannini EG, Cucchetti A, Erroi V, et al. Surveillance for early diagnosis of hepatocellular carcinoma: how best to do it? World J Gastroenterol 2013;19:8808-21. 10.3748/wjg.v19.i47.8808 - DOI - PMC - PubMed
1. Im S, Jang ES, Lee JH, et al. Surveillance rate and its impact on survival of hepatocellular carcinoma patients in South Korea: a cohort study. Cancer Res Treat 2019. [Epub ahead of print]. 10.4143/crt.2018.430 - DOI - PMC - PubMed
1. Simmons OL, Feng Y, Parikh ND, et al. Primary care provider practice patterns and barriers to hepatocellular carcinoma surveillance. Clin Gastroenterol Hepatol 2019;17:766-73. 10.1016/j.cgh.2018.07.029 - DOI - PMC - PubMed